FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150763257> ?p ?o ?g. }

• W2150763257 endingPage "3585" @default.
• W2150763257 startingPage "3577" @default.
• W2150763257 abstract "Vascular endothelial growth factor (VEGF) promotes acute myelogenous leukemia (AML) cell growth and survival and may contribute to drug resistance. bevacizumab, an anti-VEGF monoclonal antibody, exhibits clinical activity against diverse malignancies when administered with cytotoxic chemotherapy. We conducted a Phase II clinical trial of bevacizumab administered after chemotherapy to adults with refractory or relapsed AML, using a timed sequential therapy (TST) approach.bevacizumab 10 mg/kg was administered on day 8 after 1-beta-d-arabinofuranosylcytosine 2 g/m(2)/72 h beginning day 1 and mitoxantrone 40 mg/m(2) beginning day 4. In vivo laboratory correlates included AML cell VEGF receptor-1 (FLT-1) expression, marrow microvessel density, and free serum VEGF before and during TST with bevacizumab.Forty-eight adults received induction therapy. Myelosuppression occurred in all of the patients similar to other TST regimens. Toxicities were decreased ejection fraction (6%), cerebrovascular bleed (4%), and mortality of 15%. Overall response was 23 of 48 (48%), with complete response (CR) in 16 (33%). Eighteen (14 CR and 4 partial response) underwent one consolidation cycle and 5 (3 CR and 2 partial response) underwent allogeneic transplant. Median overall and disease-free survivals for CR patients were 16.2 months (64%, 1 year) and 7 months (35%, 1 year). Marrow blasts demonstrated FLT-1 staining before bevacizumab and marked decrease in microvessel density after bevacizumab. VEGF was detected in pretreatment serum in 67% of patients tested, increased by day 8 in 52%, and decreased in 93% (67% undetectable) 2 h after bevacizumab.In this single arm study, cytotoxic chemotherapy followed by bevacizumab yields a favorable CR rate and duration in adults with AML that is resistant to traditional treatment approaches. The clearance of marrow blasts in some patients after bevacizumab suggests that VEGF neutralization might result directly in leukemic cell death. The potential biological and clinical activity of bevacizumab in AML warrants additional clinical and laboratory study." @default.
• W2150763257 created "2016-06-24" @default.
• W2150763257 creator A5003107448 @default.
• W2150763257 creator A5014895157 @default.
• W2150763257 creator A5026776372 @default.
• W2150763257 creator A5028510625 @default.
• W2150763257 creator A5033174879 @default.
• W2150763257 creator A5040758762 @default.
• W2150763257 creator A5046719320 @default.
• W2150763257 creator A5051935412 @default.
• W2150763257 creator A5060944483 @default.
• W2150763257 creator A5076756822 @default.
• W2150763257 creator A5079274832 @default.
• W2150763257 date "2004-06-01" @default.
• W2150763257 modified "2023-10-01" @default.
• W2150763257 title "Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias" @default.
• W2150763257 cites W135651168 @default.
• W2150763257 cites W1562216431 @default.
• W2150763257 cites W1567732942 @default.
• W2150763257 cites W1571468897 @default.
• W2150763257 cites W182858095 @default.
• W2150763257 cites W1870350942 @default.
• W2150763257 cites W1897951801 @default.
• W2150763257 cites W1919339218 @default.
• W2150763257 cites W2003656890 @default.
• W2150763257 cites W2004907588 @default.
• W2150763257 cites W2011995063 @default.
• W2150763257 cites W2012852444 @default.
• W2150763257 cites W2029542561 @default.
• W2150763257 cites W2033902902 @default.
• W2150763257 cites W2036804890 @default.
• W2150763257 cites W2050674912 @default.
• W2150763257 cites W2059542017 @default.
• W2150763257 cites W2064297621 @default.
• W2150763257 cites W2071497118 @default.
• W2150763257 cites W2075693655 @default.
• W2150763257 cites W2084944550 @default.
• W2150763257 cites W2088211388 @default.
• W2150763257 cites W2094358576 @default.
• W2150763257 cites W2096773218 @default.
• W2150763257 cites W2102185636 @default.
• W2150763257 cites W2110630778 @default.
• W2150763257 cites W2118781121 @default.
• W2150763257 cites W2146492421 @default.
• W2150763257 cites W2157158866 @default.
• W2150763257 cites W2159137057 @default.
• W2150763257 cites W2161808292 @default.
• W2150763257 cites W2201158929 @default.
• W2150763257 cites W2331467208 @default.
• W2150763257 cites W4233279713 @default.
• W2150763257 cites W4240674955 @default.
• W2150763257 cites W4245453568 @default.
• W2150763257 cites W4245702815 @default.
• W2150763257 cites W4248836103 @default.
• W2150763257 cites W4381937407 @default.
• W2150763257 cites W4474461 @default.
• W2150763257 doi "https://doi.org/10.1158/1078-0432.ccr-03-0627" @default.
• W2150763257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15173063" @default.
• W2150763257 hasPublicationYear "2004" @default.
• W2150763257 type Work @default.
• W2150763257 sameAs 2150763257 @default.
• W2150763257 citedByCount "172" @default.
• W2150763257 countsByYear W21507632572012 @default.
• W2150763257 countsByYear W21507632572013 @default.
• W2150763257 countsByYear W21507632572014 @default.
• W2150763257 countsByYear W21507632572015 @default.
• W2150763257 countsByYear W21507632572016 @default.
• W2150763257 countsByYear W21507632572017 @default.
• W2150763257 countsByYear W21507632572018 @default.
• W2150763257 countsByYear W21507632572019 @default.
• W2150763257 countsByYear W21507632572020 @default.
• W2150763257 countsByYear W21507632572021 @default.
• W2150763257 countsByYear W21507632572022 @default.
• W2150763257 crossrefType "journal-article" @default.
• W2150763257 hasAuthorship W2150763257A5003107448 @default.
• W2150763257 hasAuthorship W2150763257A5014895157 @default.
• W2150763257 hasAuthorship W2150763257A5026776372 @default.
• W2150763257 hasAuthorship W2150763257A5028510625 @default.
• W2150763257 hasAuthorship W2150763257A5033174879 @default.
• W2150763257 hasAuthorship W2150763257A5040758762 @default.
• W2150763257 hasAuthorship W2150763257A5046719320 @default.
• W2150763257 hasAuthorship W2150763257A5051935412 @default.
• W2150763257 hasAuthorship W2150763257A5060944483 @default.
• W2150763257 hasAuthorship W2150763257A5076756822 @default.
• W2150763257 hasAuthorship W2150763257A5079274832 @default.
• W2150763257 hasConcept C126322002 @default.
• W2150763257 hasConcept C143998085 @default.
• W2150763257 hasConcept C167734588 @default.
• W2150763257 hasConcept C2776694085 @default.
• W2150763257 hasConcept C2777025900 @default.
• W2150763257 hasConcept C2777802072 @default.
• W2150763257 hasConcept C2780923524 @default.
• W2150763257 hasConcept C31760486 @default.
• W2150763257 hasConcept C71924100 @default.
• W2150763257 hasConcept C90924648 @default.
• W2150763257 hasConceptScore W2150763257C126322002 @default.
• W2150763257 hasConceptScore W2150763257C143998085 @default.
• W2150763257 hasConceptScore W2150763257C167734588 @default.

• next